FTH · Faeth Therapeutics Inc
United States · RS rating 29 · As of 2026-10-14
| Price | 20.00 USD |
|---|---|
| 1-day change | -7.0% |
| RS rating (overall / 1M / 3M / 12M) | 29 / 3 / 16 / 92 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 37 / 36 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +97.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +50.1% |
| Market cap (USD) | $459.4M |